Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference
March 22, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines...
Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer
March 21, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
March 03, 2022 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform...
Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
January 05, 2022 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors
November 17, 2021 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
November 11, 2021 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsiesInitiating a...
Longboard Pharmaceuticals Announces Steven W. Spector Joins the Company as General Counsel
November 02, 2021 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021
September 21, 2021 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial
September 08, 2021 07:00 ET
|
Longboard Pharmaceuticals, Inc.
Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin Company...